Dyadic International Inc
Dyadic International Inc is a biotechnology company focused on the development and commercialization of diagnostic and therapeutic products for the healthcare industry.
Business. Dyadic International Inc (DYAI.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Dyadic International Inc (DYAI.O) has entered the scope of analysis, marking the first available data point for the ticker with no prior basis for delta computation. This initial coverage reveals a notable shift in shareholder composition, characterized by multiple new institutional holdings detected across recent reporting periods. The most significant addition involves an investor (ID 465) who held 914,960 shares valued at approximately $0.86 million as of December 31, 2025. This position represents a weight of roughly 0.0012% of the company's equity, signaling a substantial entry relative to other recent additions. Additional notable additions were recorded as of March 31, 2026, including an investor (ID 467) holding 42,550 shares valued at $0.035 million and another (ID 517) holding 33,038 shares valued at $0.027 million. Smaller positions were also added by investors with IDs 486, 502, and 510, with share counts ranging from 178 to 32,851. These changes occur within a company profile that currently lists one officer and nine top holders, with no analyst coverage or index membership recorded. The accumulation of these new positions suggests growing institutional interest, providing a baseline for future monitoring of ownership trends and potential market impact.
Signals & dispatch
Composite-score breakdown
Synthesis
Dyadic International Inc (DYAI.O) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Dyadic International Inc has a market capitalization of $28.6 million and a price-to-book ratio of 23.2, indicating a high valuation relative to its book value. The company's liquidity position is characterized by $4.6 million in cash and equivalents, but it also carries $5.0 million in long-term debt, resulting in a debt-to-equity ratio of 4.08. The current ratio of 2.68 suggests the company has sufficient current assets to cover its current liabilities.
The company's profitability is weak, with a net loss of $7.4 million and an operating loss of $7.2 million in the latest reporting period. Return on equity is negative at -5.98%, and return on assets is also negative at -0.74%, indicating poor capital efficiency and asset utilization. The company's gross profit of $770,490 is significantly lower than its operating and net losses, highlighting the challenges in converting revenue into profit.
Dyadic International Inc operates in a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but the lack of segment or geographic breakdown suggests a relatively undiversified business model.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating cash flow is negative at -$5.7 million, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company's financial performance and cash flow position suggest a need for external financing or operational improvements to achieve sustainable growth.
The risk assessment for Dyadic International Inc indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, which is a positive sign for existing shareholders.
Recent events and disclosures for Dyadic International Inc include analyst price targets ranging from $5.00 to $7.00, with a mean and median price target of $6.00. The mean recommendation from analysts is 2.00, indicating a "buy" rating, with one analyst issuing a "buy" recommendation and none issuing a "strong buy" or "hold". These analyst estimates suggest a generally positive outlook, but the lack of strong buy ratings indicates some caution among analysts.
Dyadic International Inc (DYAI.O) has entered the scope of analysis, marking the first available data point for the ticker with no prior basis for delta computation. This initial coverage reveals a notable shift in shareholder composition, characterized by multiple new institutional holdings detected across recent reporting periods. The most significant addition involves an investor (ID 465) who held 914,960 shares valued at approximately $0.86 million as of December 31, 2025. This position represents a weight of roughly 0.0012% of the company's equity, signaling a substantial entry relative to other recent additions. Additional notable additions were recorded as of March 31, 2026, including an investor (ID 467) holding 42,550 shares valued at $0.035 million and another (ID 517) holding 33,038 shares valued at $0.027 million. Smaller positions were also added by investors with IDs 486, 502, and 510, with share counts ranging from 178 to 32,851. These changes occur within a company profile that currently lists one officer and nine top holders, with no analyst coverage or index membership recorded. The accumulation of these new positions suggests growing institutional interest, providing a baseline for future monitoring of ownership trends and potential market impact.
- Dyadic International Inc has a high price-to-book ratio of 23.2, indicating a premium valuation relative to its book value.
- The company is currently unprofitable, with a net loss of $7.4 million and an operating loss of $7.2 million.
- The company's liquidity position is mixed, with $4.6 million in cash and equivalents but a debt-to-equity ratio of 4.08.
- Analysts have a generally positive outlook, with a mean price target of $6.00 and a "buy" recommendation.
- The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,09 |
| Revenue | —no estimate | —no estimate | 6,8M USD |
| Operating income | —no estimate | —no estimate | -3,7M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
- VP of Research and Bus. Dvlpmt · Stock Option → Common StockAcquired 47 250 @ $0,94grant · 2026-01-02
- Chief Financial Officer · Stock Option → Common StockAcquired 47 250 @ $0,94grant · 2026-01-02
- Director · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
- Director · Stock Option → Common StockAcquired 67 500 @ $0,94grant · 2026-01-02
- Director · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
- Director · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
- Director · Stock Option → Common StockAcquired 67 500 @ $0,94grant · 2026-01-02
- Director · Restricted Stock Unit → Common StockAcquired 39 894grant · 2026-01-02
- Director · Restricted Stock Unit → Common StockDisposed 21 552exercise · 2026-01-02
- Director · Stock Option → Common StockAcquired 50 000 @ $0,94grant · 2026-01-02
- President & COO · Stock Option → Common StockAcquired 67 250 @ $0,94grant · 2026-01-02
- Director, CEO, 10% owner · Stock Option → Common StockAcquired 126 000 @ $0,94grant · 2026-01-02
- 10% owner · Common Stock → Common StockAcquired 238 095 @ $1,05other · 2025-12-23
- Director, CEO, 10% owner · Senior Secured Convertible Promissory Note due Dec 31, 2027 → Common StockAcquired 952 381 @ $1,05grant · 2025-12-23
- Director, CEO, 10% owner · Senior Secured Convertible Promissory Note due March 8, 2027 → Common StockDisposed 714 286 @ $1,40disposition · 2025-12-23
- Director, CEO, 10% owner · Senior Secured Convertible Promissory Note due March 8, 2027 → Common StockAcquired 714 286 @ $1,40purchase · 2025-09-15
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Dyadic International Inc Market data — financials · 2026-05-27
- Dyadic International Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Mark A. EmalfarbPresident, Chief Executive Officer, Director
Insider activity
- 10% owner · Common StockSold 2 616 @ $1,21$3K · 2026-07-24
- 10% owner · Common StockSold 54 760 @ $1,30$71K · 2026-07-23
- 10% owner · Common StockSold 38 016 @ $1,33$50K · 2026-07-22
- Director, CEO, 10% owner · Common StockOther 102 609 · 2026-01-02
- Director · Common StockOther 21 552 · 2026-01-02
- Director · Common StockOther 21 552 · 2026-01-02
- Director · Common StockOther 21 552 · 2026-01-02
- President & COO · Common StockOther 36 418 · 2026-01-02
- VP of Research and Bus. Dvlpmt · Common StockOther 18 064 · 2026-01-02
- Chief Financial Officer · Common StockOther 29 158 · 2026-01-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): -11.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -29.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 94.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -26.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -43.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.68xDerived (calculated)
- Return on assets (FY 2025-12-31): -74.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -50.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -21.9%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 5.4%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 7.07xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 16.8%Derived (calculated)
- Net margin (FY 2025-12-31): -238.3%Derived (calculated)
- Return on equity (FY 2025-12-31): -597.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -15.0%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating income (annual): USD -7.19MSEC XBRL filing
- R&D expense (annual): USD 2.15MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating cash flow (annual): USD -5.7MSEC XBRL filing
- Total liabilities (annual): USD 8.71MSEC XBRL filing
- Cash & equivalents (annual): USD 4.62MSEC XBRL filing